bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Serum Antioxidant Nutrients, Vitamin A, and Mortality in U.S. Adults
Authors: Goyal Abhishek , Terry Mary Beth , Siegel Abby B.
Published: April 2023

Abstract
Background: Observational studies have suggested that antioxidant nutrients may reduce cancer and overall mortality risks. However, most randomized trials have failed to show survival benefits. Examining nonlinear associations between antioxidant levels and health outcomes may help to explain these discrepant findings.

Methods: We evaluated all-cause, cancer, and cardiovascular mortality risks associated with quintiles (Q1–Q5) of serum antioxidant (vitamins C and E, β-carotene, and selenium) and vitamin A levels, in 16,008 adult participants of The Third National Health and Nutrition Examination Survey (NHANES III; 1988–1994).

Results: Over a median follow-up period of 14.2 years, there were 4,225 deaths, including 891 from cancer and 1,891 from cardiovascular disease. We observed a dose–response decrease in cancer and overall mortality risks with higher vitamin C levels. In contrast, for vitamin A, risk of cancer death decreased from Q1–Q2, with no further decline in risk at higher levels. For vitamin E, having levels in Q4 was associated with the lowest cancer mortality risk. Both vitamin A and E had U-shaped associations with all-cause mortality. Cancer mortality risks decreased from Q1–Q2 for β-carotene and from Q1–Q4 for selenium. However, for β-carotene and selenium, overall mortality risks decreased from Q1–Q2 but then did not change significantly with higher levels.

Conclusions: Antioxidant supplement use should be studied in the context of overall mortality and other competing mortality risks.

Impact: These data suggest the need for novel intervention studies where doses of these agents are individualized based on their serum levels, and possibly, markers of oxidative stress and systemic inflammatory response. Cancer Epidemiol Biomarkers Prev; 22(12); 2202–11. ©2013 AACR.
Data from Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study
Authors: Flanagan James M. , Brook Mark N. , Orr Nick , Tomczyk Katarzyna , Coulson Penny , Fletcher Olivia , Jones Michael E. , Schoemaker Minouk J. , Ashworth Alan , Swerdlow Anthony , Brown Robert , Garcia-Closas Montserrat
Published: April 2023

Abstract
Background: Epigenome-wide association studies (EWAS) using measurements of blood DNA methylation are performed to identify associations of methylation changes with environmental and lifestyle exposures and disease risk. However, little is known about the variation of methylation markers in the population and their stability over time, both important factors in the design and interpretation of EWAS. We aimed to identify stable variable methylated probes (VMP), i.e., markers that are variable in the population, yet stable over time.

Methods: We estimated the intraclass correlation coefficient (ICC) for each probe on the Illumina 450K methylation array in paired samples collected approximately 6 years apart from 92 participants in the Breakthrough Generations Study. We also evaluated relationships with age, reproductive and hormonal history, weight, alcohol intake, and smoking.

Results: Approximately 17% of probes had an ICC > 0.50 and were considered stable VMPs (stable-VMPs). Stable-VMPs were enriched for probes located in “shores” bordering CpG islands, and at approximately 1.3 kb downstream from the transcription start site in the transition between the unmethylated promoter and methylated gene body. Both cross-sectional and longitudinal data analyses provided strong evidence for associations between changes in methylation levels and aging. Smoking-related probes at 2q37.1 and AHRR were stable-VMPs and related to time since quitting. We also observed associations between methylation and weight changes.

Conclusion: Our results provide support for the use of white blood cell DNA methylation as a biomarker of exposure in EWAS.

Impact: Larger studies, preferably with repeated measures over time, will be required to establish associations between specific probes and exposures. Cancer Epidemiol Biomarkers Prev; 24(1); 221–9. ©2014 AACR.
Data from The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test
Authors: Schiffman Mark , Boyle Sean , Raine-Bennett Tina , Katki Hormuzd A. , Gage Julia C. , Wentzensen Nicolas , Kornegay Janet R. , Apple Raymond , Aldrich Carrie , Erlich Henry A. , Tam Thanh , Befano Brian , Burk Robert D. , Castle Philip E.
Published: April 2023

Abstract
Background: The cobas HPV Test (“cobas”; Roche Molecular Systems) detects HPV16 and HPV18 individually, and a pool of 12 other high-risk (HR) HPV types. The test is approved for (i) atypical squamous cells of undetermined significance (ASC-US) triage to determine need for colposcopy, (ii) combined screening with cytology (“cotesting”), and (iii) primary HPV screening.

Methods: To assess the possible value of HPV16/18 typing, >17,000 specimens from a longitudinal cohort study of initially HPV-positive women (HC2, Qiagen) were retested with cobas. To study accuracy, cobas genotyping results were compared with those of an established method, the Linear Array HPV Genotyping Test (LA, Roche Molecular Systems). Clinical value of the typing strategy was evaluated by linking the cobas results (supplemented by other available typing results) to 3-year cumulative risks of CIN3+.

Results: Grouped hierarchically (HPV16, else HPV18, else other HR types, else negative), the κ statistic for agreement between cobas and LA was 0.86 [95% confidence interval (CI), 0.86–0.87]. In all three scenarios, HPV16-positive women were at much higher 3-year risk of CIN3+ than HPV16-negative women: women ages 21 and older with ASC-US (14.5%; 95% CI, 13.5%–15.5% vs. 3.5%; 95% CI, 3.3–3.6); women ages 30 years and older that were HPV-positive cytology-negative (10.3%; 95% CI, 9.6–11.1 vs. 2.3%; 95% CI, 2.2–2.4); and all women 25 years and older that were HPV-positive (18.5%; 95% CI, 17.8–19.2 vs. 4.3%; 95% CI, 4.2–4.4).

Conclusion: The cobas and LA results show excellent agreement. The data support HPV16 typing.

Impact: HPV16 typing is useful in the management of HPV-positive/cytology-negative women in cotesting, of all HPV-positive women in primary HPV testing, and perhaps in the management of HPV-positive women with ASC-US. Cancer Epidemiol Biomarkers Prev; 24(9); 1304–10. ©2015 AACR.

See related commentary by Del Mistro, p. 1302
Data from Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case–Control and Family-Based Studies in Multiethnic Populations
Authors: Nakka Priyanka , Archer Natalie P. , Xu Heng , Lupo Philip J. , Raphael Benjamin J. , Yang Jun J. , Ramachandran Sohini
Published: April 2023

Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, suggesting that germline variants influence ALL risk. Although multiple genome-wide association (GWA) studies have identified variants predisposing children to ALL, it remains unclear whether genetic heterogeneity affects ALL susceptibility and how interactions within and among genes containing ALL-associated variants influence ALL risk.

Methods: Here, we jointly analyzed two published datasets of case–control GWA summary statistics along with germline data from ALL case–parent trios. We used the gene-level association method PEGASUS to identify genes with multiple variants associated with ALL. We then used PEGASUS gene scores as input to the network analysis algorithm HotNet2 to characterize the genomic architecture of ALL.

Results: Using PEGASUS, we confirmed associations previously observed at genes such as ARID5B, IKZF1, CDKN2A/2B, and PIP4K2A, and we identified novel candidate gene associations. Using HotNet2, we uncovered significant gene subnetworks that may underlie inherited ALL risk: a subnetwork involved in B-cell differentiation containing the ALL-associated gene CEBPE, and a subnetwork of homeobox genes, including MEIS1.

Conclusions: Gene and network analysis uncovered loci associated with ALL that are missed by GWA studies, such as MEIS1. Furthermore, ALL-associated loci do not appear to interact directly with each other to influence ALL risk, and instead appear to influence leukemogenesis through multiple, complex pathways.

Impact: We present a new pipeline for post hoc analysis of association studies that yields new insight into the etiology of ALL and can be applied in future studies to shed light on the genomic underpinnings of cancer. Cancer Epidemiol Biomarkers Prev; 26(10); 1531–9. ©2017 AACR.
Data from Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry
Authors: Mocci Evelina , Milne Roger L. , Méndez-Villamil Elena Yuste , Hopper John L. , John Esther M. , Andrulis Irene L. , Chung Wendy K. , Daly Mary , Buys Saundra S. , Malats Nuria , Goldgar David E.
Published: April 2023

Abstract
Background: Increased risk of pancreatic cancer has been reported in breast cancer families carrying BRCA1and BRCA2 mutations; however, pancreatic cancer risk in mutation-negative (BRCAX) families has not been explored to date. The aim of this study was to estimate pancreatic cancer risk in high-risk breast cancer families according to the BRCA mutation status.

Methods: A retrospective cohort analysis was applied to estimate standardized incidence ratios (SIR) for pancreatic cancer. A total of 5,799 families with ≥1 breast cancer case tested for mutations in BRCA1 and/or BRCA2 were eligible. Families were divided into four classes: BRCA1, BRCA2, BRCAX with ≥2 breast cancer diagnosed before age 50 (class 3), and the remaining BRCAX families (class 4).

Results:BRCA1 mutation carriers were at increased risk of pancreatic cancer [SIR = 4.11; 95% confidence interval (CI), 2.94–5.76] as were BRCA2 mutation carriers (SIR = 5.79; 95% CI, 4.28–7.84). BRCAX family members were also at increased pancreatic cancer risk, which did not appear to vary by number of members with early-onset breast cancer (SIR = 1.31; 95% CI, 1.06–1.63 for class 3 and SIR = 1.30; 95% CI, 1.13–1.49 for class 4).

Conclusions: Germline mutations in BRCA1 and BRCA2 are associated with an increased risk of pancreatic cancer. Members of BRCAX families are also at increased risk of pancreatic cancer, pointing to the existence of other genetic factors that increase the risk of both pancreatic cancer and breast cancer.

Impact: This study clarifies the relationship between familial breast cancer and pancreatic cancer. Given its high mortality, pancreatic cancer should be included in risk assessment in familial breast cancer counseling. Cancer Epidemiol Biomarkers Prev; 22(5); 803–11. ©2013 AACR.
Data from Exploring the Linkage between Activity-Friendly Zoning, Inactivity, and Cancer Incidence in the United States
Authors: Nicholson Lisa M. , Leider Julien , Chriqui Jamie F.
Published: April 2023

Abstract
Background: Physical activity (PA) protects against cancer and enhances cancer survivorship. Given high inactivity rates nationwide, population-level physical activity facilitators are needed. Several authoritative bodies have recognized that zoning and planning helps create activity-friendly environments. This study examined the association between activity-friendly zoning, inactivity, and cancer in 478 of the most populous U.S. counties.

Methods: County geocodes linked county-level data: cancer incidence and smoking (State Cancer Profiles), inactivity (Behavioral Risk Factor Surveillance System), 11 zoning measures (compiled by the study team), and covariates (from the American Community Survey and NAVTEQ). For each zoning measure, single mediation regression models and Sobel tests examined whether activity-friendly zoning was associated with reduced cancer incidence, and whether inactivity mediated those associations. All models were clustered on state with robust SEs and significance at the P < 0.05 level.

Results: Zoning for crosswalks, bike–pedestrian connectivity, and bike–pedestrian trails/paths were associated with reduced cancer incidence (β between −0.71 and −1.27, P < 0.05), about 1 case per 100,000 for each 10 percentage-point increase in county population exposure to zoning. Except for crosswalks, each association was mediated by inactivity. However, county smoking attenuated these results, with only crosswalks remaining significant. Results were similar for males (with zoning for bike–pedestrian connectivity, street connectivity, and bike–pedestrian trails/paths), but not females, alone.

Conclusions: Zoning can help to create activity-friendly environments that support decreased inactivity, and possibly reduced cancer incidence.

Impact: Given low physical activity levels nationwide, cross-sectoral collaborations with urban planning can inform cancer prevention and public health efforts to decrease inactivity and cancer. Cancer Epidemiol Biomarkers Prev; 26(4); 578–86. ©2017 AACR.

See all the articles in this CEBP Focus section, “Geospatial Approaches to Cancer Control and Population Sciences.”
Supplementary Movie S7 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Authors: Jackson Lindsey N. , Chen L. Andy , Larson Shawn D. , Silva Scott R. , Rychahou Piotr G. , Boor Paul J. , Li Jing , DeFreitas Gilberto , Stafford W. Lane , Townsend Courtney M. , Evers B. Mark
Published: April 2023

Supplementary Movie S7 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Supplementary Movie S6 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Authors: Jackson Lindsey N. , Chen L. Andy , Larson Shawn D. , Silva Scott R. , Rychahou Piotr G. , Boor Paul J. , Li Jing , DeFreitas Gilberto , Stafford W. Lane , Townsend Courtney M. , Evers B. Mark
Published: April 2023

Supplementary Movie S6 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Supplementary Movie S4 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Authors: Jackson Lindsey N. , Chen L. Andy , Larson Shawn D. , Silva Scott R. , Rychahou Piotr G. , Boor Paul J. , Li Jing , DeFreitas Gilberto , Stafford W. Lane , Townsend Courtney M. , Evers B. Mark
Published: April 2023

Supplementary Movie S4 from Development and Characterization of a Novel In vivo Model of Carcinoid Syndrome
Supplementary Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia
Authors: Friedman Daphne R. , Weinberg J. Brice , Barry William T. , Goodman Barbara K. , Volkheimer Alicia D. , Bond Karen M. , Chen Youwei , Jiang Ning , Moore Joseph O. , Gockerman Jon P. , Diehl Louis F. , Decastro Carlos M. , Potti Anil , Nevins Joseph R.
Published: April 2023

Supplementary Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia
Supplementary Data from A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples
Authors: Sánchez-Espiridión Beatriz , Sánchez-Aguilera Abel , Montalbán Carlos , Martin Carmen , Martinez Rafael , González-Carrero Joaquín , Poderos Concepción , Bellas Carmen , Fresno Manuel F. , Morante Cesar , Mestre Maria J. , Mendez Miguel , Mazorra Francisco , Conde Eulogio , Castaño Angel , Sánchez-Godoy Pedro , Tomas José F. , Morente Manolo M. , Piris Miguel A. , García Juan F.
Published: April 2023

Supplementary Data from A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples
Supplementary Data from Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases
Authors: Bedolla Roble G. , Wang Yu , Asuncion Alfredo , Chamie Karim , Siddiqui Salma , Mudryj Maria M. , Prihoda Thomas J. , Siddiqui Javed , Chinnaiyan Arul M. , Mehra Rohit , de Vere White Ralph W. , Ghosh Paramita M.
Published: April 2023

Supplementary Data from Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases
Supplementary Data from Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer
Authors: Arredouani Mohamed S. , Lu Bin , Bhasin Manoj , Eljanne Miriam , Yue Wen , Mosquera Juan-Miguel , Bubley Glenn J. , Li Vivian , Rubin Mark A. , Libermann Towia A. , Sanda Martin G.
Published: April 2023

Supplementary Data from Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer
Supplementary Data from Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes
Authors: Huang Yi , Stewart Tracy Murray , Wu Yu , Baylin Stephen B. , Marton Laurence J. , Perkins Brandy , Jones Richard J. , Woster Patrick M. , Casero Robert A.
Published: April 2023

Supplementary Data from Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes
Supplementary Figure 3 from Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Authors: Tzelepi Vassiliki , Zhang Jiexin , Lu Jing-Fang , Kleb Brittany , Wu Guanglin , Wan Xinhai , Hoang Anh , Efstathiou Eleni , Sircar Kanishka , Navone Nora M. , Troncoso Patricia , Liang Shoudan , Logothetis Christopher J. , Maity Sankar N. , Aparicio Ana M.
Published: April 2023

PDF file - 150K, A: Mitotic figures in the xenografts; left panel: graphical presentation of the number of mitotic figures in SCPC/LCNEC xenografts (mean 11 mitoses per high power field) and adenocarcinoma xenografts (mean 2 per high power field); right panel: pictures from H&E stained slides of a SCPC and an adenocarcinoma (AdCa) xenograft. Arrows point to the mitotic figures. B: Higher expression levels of ki67 are noted in the SCPC/LCNEC xenografts and clinical samples compared to adenocarcinomas C:Flow cytometry of SCPC xenograft 146-10 and adenocarcinoma xenograft 180-30. (SCPC, small-cell prostate carcinoma; LCNEC, large-cell neuroendocrine carcinoma).
Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Table 4. Transcripts that contribute to the SVM_th10 classifier. This supplementary table highlights the transcripts that constitute the SVM_th10 classifier. Indicated for each feature are the Oligo-ID, the Gene symbols, the Entrez gene IDs, the RefSeq IDs, the Gene IDs and the Transcript IDs.
Supplementary Table 1, Supplementary Table 2, Supplementary Table 3, or Supplementary Table 4 from Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
Authors: Matsusaka Satoshi , Hanna Diana L. , Cao Shu , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Okazaki Satoshi , Berger Martin D. , Miyamato Yuji , Parekh Anish , Stintzing Sebastian , Loupakis Fotios , Lenz Heinz-Josef
Published: April 2023

Supplementary Table 1. Associations between baseline characteristics and clinical outcomes in the training cohort (TRIBE) Supplementary Table 2. Associations between baseline characteristics and clinical outcomes in the validation cohort (FIRE-3) Supplementary Table 3. Associations between baseline characteristics and clinical outcomes in the control cohort (FIRE-3) Supplementary Table 4. Association between IL-6, STAT3 SNPs with clinical outcomes in the training cohort
Supplementary Figure 4 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 1 MB, Immunoblotting of c-Myc in (A) T4302 CD133+ cells or (B) T4302 CD133-cells treated with JQ1 for 24 hours at indicated concentrations.
Supplementary Table S3 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Table S3. Clinicopathologic features of patients with gastric cancer according to the expression status of TMEFF2.
Supplementary Figure S1-S6 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Figure S1. Identification of TMEFF2 as a key regulator in gastric cancer progression and the expression of TMEFF2 decreased in gastric carcinogenesis. Supplementary Figure S2. Gene Set Enrichment Analysis (GSEA) in TMEFF2-higher/lower expression patients. Supplementary Figure S3. The mRNA levels of the top-score tumorigenesis genes were measured in gastric cells after transfection of TMEFF2 overexpression plasmid or siRNA Supplementary Figure S4. Functional impact of TMEFF2 Supplementary Figure S5. Cell proliferation assays were performed in MKN45 cells after overexpression of SHP-1WT/Î”SH2D1/Î”SH2D2/Î”PTPD or these constructs combined with TMEFF2. n = 3, non-parametric Mann-Whitney test. Supplementary Figure S6. Correlation of TMEFF2 and SHP-1 expression in human GC.
Table S1 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Supplementary table showing demographic information and protein docing.
Supplementary Table 1 from Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Pinker-Domenig Katja , Berzaczy Dominik , Hoffmann Martha , Sillaber Christian , Jaeger Ulrich , Müllauer Leonhard , Simonitsch-Klupp Ingrid , Dolak Werner , Gaiger Alexander , Ubl Philipp , Lukas Julius , Raderer Markus
Published: April 2023

PDF file - 24KB, Region-based results for DWI-MRI in Group A (DLBCL, follicular lymphoma, Hodgkin lymphoma, nMZL, MCL, peripheral T-cell lymphoma, and ALCL), and DWIMRI, 18F-FDG-PET/CT, and CE-CT in Group B (MALT lymphoma, SLL/CLL): true-positive (TP), false-negative (FN), false-positive (FP), and true negative (TN) regions.
Data Supplement from Intraperitoneal Oxidative Stress in Rabbits with Papillomavirus-Associated Head and Neck Cancer Induces Tumoricidal Immune Response That Is Adoptively Transferable
Authors: Rossmann Annette , Mandic Robert , Heinis Jochen , Höffken Helmut , Küssner Oliver , Kinscherf Ralf , Weihe Eberhard , Bette Michael
Published: April 2023

Supplementary Table 1. Hemogram of rabbits, which respond to O3/O2-PP treatment by tumor clearance (n=7) and of rabbits, which showed a clear tumor progression after sham treatment (n=6). Blood parameters were measured before induction of the auricular VX2 tumor (base value) and of VX2 tumor bearing rabbits directly before and after the treatment schema. â€¡ The base value includes blood parameter from animals of both treatment schema (n=13). Statistically significant changes between values before and after a treatment were marked with p<0.05. Abbreviations: WBC (White blood cells), RBC (Red blood cells), PLT (Platelets), HGB (Hemoglobin), HCT (Hematocrit), MCV (mean corpuscular volume), MCH (mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentration)
Data Supplement from Intraperitoneal Oxidative Stress in Rabbits with Papillomavirus-Associated Head and Neck Cancer Induces Tumoricidal Immune Response That Is Adoptively Transferable
Authors: Rossmann Annette , Mandic Robert , Heinis Jochen , Höffken Helmut , Küssner Oliver , Kinscherf Ralf , Weihe Eberhard , Bette Michael
Published: April 2023

Supplementary Table 2A. Complete RT2 Profiler PCR Array 1. Overview of all genes analyzed by the RT2 Profiler PCR Array (SABiosciences, PANZ-052ZA). Fold changes of mRNA expression level measured in remitting VX2 tumors in the cause of the O3/O2-PP therapy (Regression, n=6) were calculated in reference to mRNA level measured in growing VX2 tumors of sham treated animals (Progression, n=6). Regulation of mRNA level is marked by â†‘ (up) or â†“ (down). Statistic differences were calculated by the paired t-test and marked as: *p<0.05; **p<0.01; ***p<0.001; n.s. not significant.
Supplementary figure 3 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 3: Blood vessels are located in the peritumoral areas of cSCCs.
Supplementary Table 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Table 2 - Summary of evaluated candidate SNPs in patients with NE in E1199 or E5103.
Supplementary Figures S1-7, Tables S1-5 from The miR-30 Family Inhibits Pulmonary Vascular Hyperpermeability in the Premetastatic Phase by Direct Targeting of Skp2
Authors: Qi Feifei , He Ting , Jia Lin , Song Nan , Guo Lifang , Ma Xuhui , Wang Chunying , Xu Min , Fu Yan , Li Lin , Luo Yongzhang
Published: April 2023

Supplementary Figures S1-7, Tables S1-5. Supplementary Figure S1. In situ detection of miR-30s in mouse cryosections from normal and premetastatic lung tissues. Supplementary Figure S2. miR-30s were downregulated in the premetastatic niche. Supplementary Figure S3. miR-30s inhibited lung metastasis. Supplementary Figure S4. Identification targets of miR-30s in premetastatic niche. Supplementary Figure S5. Screening for targets of miR-30s in premetastatic niche. Supplementary Figure S6. Function of miR-30 targets in pulmonary vascular destabilization. Supplementary Figure S7. Tumor volumes of 4T1 tumor-bearing mice. Supplementary Table S1: siRNA sequences used in this study Supplementary Table S2: Primers used in this study Supplementary Table S3: miRNA probes used in this study Supplementary Table S4: Confirmation of downregulated miRNAs in premetastatic lung samples at different time point using qRT-PCR Supplementary Table S5. The co-expression analysis of miR-30s and miR-30s' targets in premetastatic lung samples (Pearson correlation analysis)
Supplementary Figure Legend from Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Authors: Wang Don-Hong , Lee Hyun-Sung , Yoon David , Berry Gerald , Wheeler Thomas M. , Sugarbaker David J. , Kheradmand Farrah , Engleman Edgar , Burt Bryan M.
Published: April 2023

Supplementary Figure Legend
Supplemental Figure Legends from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Supplemental Figure Legends
Supplemental Information from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Material and Methods describing CEA TCB production and purification process, determination of affinity and avidity, genetic characterization of cell lines, determination of CEA binding sites, assessment of T cell proliferation and activation, Jurkat NFAT assay, confocal microscopy, FRET, SDPK, in vivo efficacy and imaging studies. Supplemental Video Legends are also within the file.
Supplementary Methods, Table 1 from Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Authors: Wilson Melissa A. , Zhao Fengmin , Letrero Richard , D'Andrea Kurt , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Lee Sandra J. , Schuchter Lynn M. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

PDF file - 149KB, Supplemental Table 1. Multivariable logistic regression for BRAF and NRAS mutations.
Supplementary data from The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway
Authors: Beider Katia , Rosenberg Evgenia , Bitner Hanna , Shimoni Avichai , Leiba Merav , Koren-Michowitz Maya , Ribakovsky Elena , Klein Shiri , Olam Devorah , Weiss Lola , Wald Hanna , Abraham Michal , Galun Eithan , Peled Amnon , Nagler Arnon
Published: April 2023

Contains supplementary methods and primer sequences
Video 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Authors: Zullo Kelly M. , Guo Yige , Cooke Laurence , Jirau-Serrano Xavier , Mangone Michael , Scotto Luigi , Amengual Jennifer E. , Mao Yinghui , Nandakumar Renu , Cremers Serge , Duong Jimmy , Mahadevan Daruka , O'Connor Owen A.
Published: April 2023

Video 1. Using a live cell imaging system, H9 cell line was treated from 0- 72 hours with (A) Untreated Control (B) 2 nM Romidepsin (C) 100 nM Alisertib (D) 2nM Romidepsin and 100 nM Alisertib. Videos demonstrate live cell imaging of H9 during the specific treatment condition mentioned above. In video (A), the arrow follows the same cell undergoing normal mitosis.
Supplementary Figure 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Authors: Zullo Kelly M. , Guo Yige , Cooke Laurence , Jirau-Serrano Xavier , Mangone Michael , Scotto Luigi , Amengual Jennifer E. , Mao Yinghui , Nandakumar Renu , Cremers Serge , Duong Jimmy , Mahadevan Daruka , O'Connor Owen A.
Published: April 2023

Supplementary Figure 1. 0.75 nM of PDX in combination with 100 nM of alisertib was obsereved in a schedule dependent manner to evaluate drug:drug interactions. Simultaneous incubation of drugs is depicted as (I), while schedule (drug A before Drug B and Drug B before Drug A) is depicted as (II). (A) The histogram (to the left) demonstrates simultaneous and 24 hourpre-exposure of alisertib followed by PDX in H9 cell line. The histogram (to the right) demonstrates simultaneous and 24 hour pre-exposure of PDX followed by alisertib in H9 cell lines. (B) SU-DHL6 cell line demonstrated a lack of synergy following simultaneous incubation as well as 24 hour pre-exposure of 0.75 nM of PDX followed by 50 nM of alisertib. (C) Simultaneous incubation of alisertib with Ixazomib following 72 hours was not synergistic in H9 cell line. (D) Simultaneous incubation of alisertib with ixazomib following 72hours was not synergistic in SU-DHL6 cell line.
Supplemental Figure S1 from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental Figure S1. Relative expression of Ebp1 in primary AML cells as compared to normal mononuclear cells.
Supplementary Table 2 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 135K, Supplementary table 2. Donor 1 PBMC delta chain diversity.
Supplementary Figure 5 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 91K, Supplementary figure 5. GD2 staining of neuroblastoma cell lines.
Supplementary Figure S1 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

FBW7 regulates downstream genes in the glycolysis process of pancreatic cancer.
Supplementary Figure Legends from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Authors: Sterman Daniel H. , Alley Evan , Stevenson James P. , Friedberg Joseph , Metzger Susan , Recio Adri , Moon Edmund K. , Haas Andrew R. , Vachani Anil , Katz Sharyn I. , Sun Jing , Heitjan Daniel F. , Hwang Wei-Ting , Litzky Leslie , Yearley Jennifer H. , Tan Kay See , Papasavvas Emmanouil , Kennedy Paul , Montaner Luis J. , Cengel Keith A. , Simone Charles B. , Culligan Melissa , Langer Corey J. , Albelda Steven M.
Published: April 2023

Legends for the Supplementary Figures
Supplementary Table 5 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Authors: Wynes Murry W. , Hinz Trista K. , Gao Dexiang , Martini Michael , Marek Lindsay A. , Ware Kathryn E. , Edwards Michael G. , Böhm Diana , Perner Sven , Helfrich Barbara A. , Dziadziuszko Rafal , Jassem Jacek , Wojtylak Szymon , Sejda Aleksandra , Gozgit Joseph M. , Bunn Paul A. , Camidge D. Ross , Tan Aik-Choon , Hirsch Fred R. , Heasley Lynn E.
Published: April 2023

XLSX file - 106KB, Table S5. Tabulated FGFR1, FGF2 and FGF9 mRNA expression values, FGFR1 CNV values and mutation status of TCGA lung adenocarcinomas and squamous cell carcinomas.
Supplementary Figure Legends, Figures 1 - 7 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Authors: Wynes Murry W. , Hinz Trista K. , Gao Dexiang , Martini Michael , Marek Lindsay A. , Ware Kathryn E. , Edwards Michael G. , Böhm Diana , Perner Sven , Helfrich Barbara A. , Dziadziuszko Rafal , Jassem Jacek , Wojtylak Szymon , Sejda Aleksandra , Gozgit Joseph M. , Bunn Paul A. , Camidge D. Ross , Tan Aik-Choon , Hirsch Fred R. , Heasley Lynn E.
Published: April 2023

PDF file - 786KB, Figure S1. FGFR1 immunoblots of extracts from lung cancer cell lines representative of the 58 cell lines employed in the studies. Figure S2. Images and quantification of clonogenic growth assays in selected lung cancer cell lines following shRNA-mediated FGFR1 silencing. Figure S3. Dose response curve for inhibition of Colo699 cell growth by the FGF ligand trap, FP-1039. Figure S4. Venn diagram of the overlap of FGFR1, FGF2 and FGF9 expression in ponatinib-sensitive lung cancer cell lines and splicing status of FGFR2 in H1581 and H1048 cells. Figure S5. Graph of ROC analysis of FGFR1 GCN and mRNA expression in a TMA comprised of 21 lung cancer cell lines. Figure S6. Kaplan-Meier analysis of overall survival of lung cancer patients with increased FGFR1 GCN or high mRNA. Figure S7. Venn diagram showing overlap of FGF2 and FGF9 expression with FGFR1 mRNA positivity in primary lung squamous cell carcinomas and adenocarcinomas analyzed by the Cancer Genome Atlas.
Supplementary Figures 1-8 from ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer
Authors: Gao Shuai , Ye Huihui , Gerrin Sean , Wang Hongyun , Sharma Ankur , Chen Sen , Patnaik Akash , Sowalsky Adam G. , Voznesensky Olga , Han Wanting , Yu Ziyang , Mostaghel Elahe A. , Nelson Peter S. , Taplin Mary-Ellen , Balk Steven P. , Cai Changmeng
Published: April 2023

Figure S1. The expressions of ERBB2 and ERBB3 are not increased by androgen deprivation; Figure S2. AR mRNA expression was not significantly decreased by lapatinib in LAPC4-CR cells; Figure S3. Lapatinib can block heregulin stimulated ErbB2 activation in C4-2 cells; Figure S4. Lapatinib decreased AR protein expression at 8h treatement; Figure S5. AR mRNA expression was not significantly decreased by lapatinib or AKT-x in C4-2 cells; Figure S6. AR protein nuclear expression was decreased by siRNA against ERBB2; Figure S7. AKT inhibitor treatment decreased AR protein expression and activity; Figure S8. Silencing PIK3CB expression decreased AR protein expression.
Supplemental figure 3 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

Supplemental figure 3. Association of cytokine production and LFT. Shown on left are serum cytokine levels for IL12 and IFNg over two week period. Shown on right are LFT for aspartate aminotransferase, alkaline phosphatase, and alanine aminotransferase over a two week period. Values shown were obtained from patient 24.
supplementary table 1 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Authors: Napolitano Stefania , Martini Giulia , Rinaldi Barbara , Martinelli Erika , Donniacuo Maria , Berrino Liberato , Vitagliano Donata , Morgillo Floriana , Barra Giusy , De Palma Raffaele , Merolla Francesco , Ciardiello Fortunato , Troiani Teresa
Published: April 2023

supplementary table 1. mutational status
Supplemental Figure 2 from First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Authors: Starodub Alexander N. , Ocean Allyson J. , Shah Manish A. , Guarino Michael J. , Picozzi Vincent J. , Vahdat Linda T. , Thomas Sajeve S. , Govindan Serengulam V. , Maliakal Pius P. , Wegener William A. , Hamburger Steven A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Time to progression in relation to the immunohistological score in 16 patients with diverse cancers enrolled in the sacituzumab govitecan trial who provided archival tissue specimens.
Supplementary Figure 1 from A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases
Authors: Balachandran Vinod P. , Arora Arshi , Gönen Mithat , Ito Hiromichi , Turcotte Simon , Shia Jinru , Viale Agnes , Snoeren Nikol , van Hooff Sander R. , Rinkes Inne H.M. Borel , Adam René , Kingham T. Peter , Allen Peter J. , DeMatteo Ronald P. , Jarnagin William R. , D'Angelica Michael I.
Published: April 2023

Genes selected for molecular risk score (MRS).
Supplementary figure 1 from SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Authors: Tang Sai-Wen , Bilke Sven , Cao Liang , Murai Junko , Sousa Fabricio G. , Yamade Mihoko , Rajapakse Vinodh , Varma Sudhir , Helman Lee J. , Khan Javed , Meltzer Paul S. , Pommier Yves
Published: April 2023

Supplementary figure 1. The protein levels of SLFN11 in 25 EWS-FLI1-expressing cells (black) and 4 EWS-ERG-expressing cells (red) were detected by Western blotting using antibodies against SLFN11 (98 kDa) and actin (42 kDa, loading control). The relative SLFN11 levels of each cell line were normalized to actin levels and the SLFN11/actin ratio of TC-106 was set as 1.
Supplementary Figure 4 from Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia
Authors: Coltella Nadia , Valsecchi Roberta , Ponente Manfredi , Ponzoni Maurilio , Bernardi Rosa
Published: April 2023

Supplementary Figure 4: Combined effect of EZN-2208 and ATRA on NB4 cell viability and differentiation.
Supplementary Figure 3 from Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia
Authors: Coltella Nadia , Valsecchi Roberta , Ponente Manfredi , Ponzoni Maurilio , Bernardi Rosa
Published: April 2023

Supplementary Figure 3: EZN-2208 affects leukemic stromal cell numbers.
Supplemental Table S6 from Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Authors: Morin Ryan D. , Assouline Sarit , Alcaide Miguel , Mohajeri Arezoo , Johnston Rebecca L. , Chong Lauren , Grewal Jasleen , Yu Stephen , Fornika Daniel , Bushell Kevin , Nielsen Torsten Holm , Petrogiannis-Haliotis Tina , Crump Michael , Tosikyan Axel , Grande Bruno M. , MacDonald David , Rousseau Caroline , Bayat Maryam , Sesques Pierre , Froment Remi , Albuquerque Marco , Monczak Yury , Oros Kathleen Klein , Greenwood Celia , Riazalhosseini Yasser , Arseneault Madeleine , Camlioglu Errol , Constantin André , Pan-Hammarstrom Qiang , Peng Roujun , Mann Koren K. , Johnson Nathalie A.
Published: April 2023

Targeted capture sequencing
Supplementary Methods and Materials, Tables S1-S6 from Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Authors: Lum Lawrence G. , Thakur Archana , Al-Kadhimi Zaid , Colvin Gerald A. , Cummings Francis J. , Legare Robert D. , Dizon Don S. , Kouttab Nicola , Maizel Abby , Colaiace William , Liu Qin , Rathore Ritesh
Published: April 2023

Methods and Materials, Supplementary Tables S1-S6. Table S1. Patient characteristics: Prior chemotherapy, ER/PR/HER2 status, aATC dose, disease status, survival and time to progression data. Table S2. Dose Escalation Table S3. Characteristics and Activity of Expansion Product Table S4. Clinical Outcomes: Stable Disease at 14.5 Weeks versus Progressive Disease in HER2 negative and HER2 3+ Metastatic Breast Cancer Patients. Table S5. Clinical Responses to HER2Bi-armed ATC by Dose Level in Phase I Metastatic Breast Cancer (HER2/neu 0-3+) at 14.5 Weeks after Last Chemotherapy/Hormone Treatment. Table S6. Shows tumor marker responses in 14 patients post immunotherapy from base line before IT treatment.
Supplementary Table 2S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Cox regression analyses with three way interaction stratified by either MSKCC or HENG risk.
Supplemental Table 1 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Authors: Olow Aleksandra , Mueller Sabine , Yang Xiaodong , Hashizume Rintaro , Meyerowitz Justin , Weiss William , Resnick Adam C. , Waanders Angela J. , Stalpers Lukas J.A. , Berger Mitchel S. , Gupta Nalin , James C. David , Petritsch Claudia K. , Haas-Kogan Daphne A.
Published: April 2023

In vitro cell line IC50 values and mutational status.
Figure S2 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Figure S2. Effect of all-trans retinoic acid (ATRA) on daratumumab-induced CDC.CLL cells (n=6) were treated with 10nM ATRA or left untreated for 48h. CD38 expression was analyzed subsequently (CD19-FITC CD5-PECy5 CD38PE).
Supplemental Figure 4 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

R3Mab reduces MMP protein secretion in the conditioned medium by UMUC-14 cells.
Supplementary Figure 4 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Performance of the radiation sensitivity signature with the previously published radiation sensitivity signature in the validation dataset.
Supplementary Figure 4 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 4. Metabolic protein expression analysis supporting Figure 4 along with lactate measurements in normal spinal tissue, Grade II spinal ependymoma, and myxopapillary ependymoma.
Table S2 from The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Authors: Choi Stephen Yiu Chuen , Xue Hui , Wu Rebecca , Fazli Ladan , Lin Dong , Collins Colin C. , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Additional Clinicopathological Characteristics associated with high MCT4 expression in patient samples.